Liposomal bupivacaine is one of 285 small molecule programs targeting Total Joint Arthroplasty. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
686 competitors in Lung Cancer
Liposomal bupivacaine
Tecentriq
Libtayo
Vizimpro
Talzenna
Folvite
Immunotherapy
Paclitaxel and Carboplatin
Rilotumumab
Acupan
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details